MEDP · Medpace Holdings
10 filings
MEDP 10-K Annual Reports
Medpace Holdings - 10 annual reports
MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.
- 8-K · Aug 16, 2016
- 8-K · Oct 28, 2016
- 10-Q · Nov 3, 2016
- 8-K · Nov 3, 2016
- 8-K · Dec 8, 2016
- 8-K · Feb 27, 2017
- 8-K · Feb 28, 2017
- 10-K · Feb 28, 2017
- 8-K · May 1, 2017
- 10-Q · May 2, 2017
- 8-K · May 23, 2017
- 8-K · Jun 15, 2017
- 8-K · Jun 21, 2017
- 8-K · Jul 31, 2017
- 10-Q · Aug 1, 2017
- 8-K · Aug 22, 2017
- 8-K · Oct 30, 2017
- 10-Q · Oct 31, 2017
- 8-K · Dec 5, 2017
- 8-K · Feb 26, 2018
- 10-K · Feb 27, 2018
- 8-K · Apr 30, 2018
- 10-Q · May 1, 2018
- 8-K · May 4, 2018
- 8-K · May 23, 2018
- 8-K · Jun 8, 2018
- 8-K · Jun 13, 2018
- 8-K · Jul 30, 2018
- 10-Q · Jul 31, 2018
- 8-K · Aug 6, 2018
- 8-K · Aug 9, 2018
- 8-K · Aug 13, 2018
- 8-K · Aug 24, 2018
- 8-K · Aug 31, 2018
- 8-K · Oct 29, 2018
- 10-Q · Oct 30, 2018
- 8-K · Feb 25, 2019
- 10-K · Feb 26, 2019
- 8-K · Apr 16, 2019
- 8-K · Apr 29, 2019
- 10-Q · Apr 30, 2019
- 8-K · May 17, 2019
- 8-K · May 21, 2019
- 8-K · May 24, 2019
- 8-K · Jul 29, 2019
- 10-Q · Jul 30, 2019
- 8-K · Oct 1, 2019
- 8-K · Oct 25, 2019
- 8-K · Oct 28, 2019
- 10-Q · Oct 29, 2019
- 8-K · Feb 24, 2020
- 10-K · Feb 25, 2020
- 8-K · Mar 5, 2020
- 8-K · Apr 1, 2020
- 8-K · Apr 28, 2020
- 10-Q · Apr 29, 2020
- 8-K · May 21, 2020
- 8-K · Jul 27, 2020
- 10-Q · Jul 28, 2020
- 8-K · Oct 26, 2020
- 10-Q · Oct 27, 2020
- 8-K · Oct 30, 2020
- 8-K · Feb 16, 2021
- 10-K · Feb 16, 2021
- 8-K · Mar 30, 2021
- 8-K · Apr 26, 2021
- 10-Q · Apr 27, 2021
- 8-K · May 14, 2021
- 8-K · Jun 11, 2021
- 8-K · Jul 23, 2021
- 8-K · Jul 26, 2021
- 8-K · Jul 26, 2021
- 10-Q · Jul 27, 2021
- 8-K · Oct 25, 2021
- 10-Q · Oct 26, 2021
- 8-K · Dec 29, 2021
- 8-K · Feb 14, 2022
- 10-K · Feb 15, 2022
- 8-K · Mar 16, 2022
- 8-K · Apr 25, 2022
- 10-Q · Apr 26, 2022
- 8-K · May 20, 2022
- 8-K · May 26, 2022
- 8-K · Jun 10, 2022
- 8-K · Jul 25, 2022
- 10-Q · Jul 26, 2022
- 8-K · Oct 24, 2022
- 10-Q · Oct 25, 2022
- 8-K · Jan 3, 2023
- 8-K · Jan 18, 2023
- 8-K · Feb 13, 2023
- 10-K · Feb 14, 2023
- 8-K · Mar 31, 2023
- 8-K · Apr 24, 2023
- 10-Q · Apr 25, 2023
- 8-K · May 19, 2023
- 8-K · Jul 24, 2023
- 10-Q · Jul 25, 2023
- 8-K · Oct 23, 2023
- 10-Q · Oct 24, 2023
- 8-K · Feb 12, 2024
- 10-K · Feb 13, 2024
- 8-K · Mar 29, 2024
- 8-K · Apr 22, 2024
- 10-Q · Apr 23, 2024
- 8-K · May 21, 2024
- 8-K · Jul 3, 2024
- 8-K · Jul 22, 2024
- 10-Q · Jul 23, 2024
- 8-K · Oct 21, 2024
- 10-Q · Oct 22, 2024
- 8-K · Feb 10, 2025
- 10-K · Feb 11, 2025
- 8-K · Mar 31, 2025
- 8-K · Apr 21, 2025
- 10-Q · Apr 22, 2025
- 8-K · May 16, 2025
- 8-K · Jul 21, 2025
- 10-Q · Jul 22, 2025
- 8-K · Oct 22, 2025
- 10-Q · Oct 23, 2025
- 8-K · Feb 9, 2026
- 10-K · Feb 10, 2026
- 8-K · Apr 22, 2026
- 10-Q · Apr 23, 2026
- 8-K · May 19, 2026
- 8-K · Jun 4, 2026
- 8-K · Jul 22, 2026
- 10-Q · Jul 23, 2026
- 8-K · Oct 21, 2026
- 10-Q · Oct 22, 2026
- 2025Feb 10, 2026
Medpace Holdings Annual Report, Year Ended Dec 31, 2025
Medpace Holdings, Inc. reported record 2025 results, with net revenue of $2,530,234 thousand ($2.53 billion), up from $2,109,054 thousand in 2024, and net income of $451,123 thousand ($451.1 million), up from $404,386 thousand. Income from operations rose to $534,935 thousand from $446,870 thousand. Diluted EPS was $15.28, compared with $12.63 in 2024. Growth was led by Metabolic, Oncology and Central Nervous System activity, and reimbursed out-of-pocket expenses, which fluctuate with program timing, rose $266.8 million and drove much of the increase in total direct costs. Net new business awards were $2,646.8 million in 2025 versus $2,230.0 million in 2024, and backlog increased $125.0 million, or 4.3%, to $3,027.2 million at December 31, 2025. Approximately $1,890.0 million to $1,910.0 million of that backlog is expected to convert to net revenue in 2026. The filing notes that backlog is contractually terminable without cause and is not necessarily a meaningful predictor of future results. Capital allocation was dominated by share repurchases. The company repurchased shares for $912.9 million in 2025, ended the year with $497.0 million in cash and cash equivalents, and reported no indebtedness. Remaining repurchase authorization was $821.7 million. The filing also discloses concentration and governance considerations: the top ten customers provided approximately 35.1% of net revenue, and CEO and founder August J. Troendle controls approximately 19.0% of outstanding shares.
- 2024Feb 11, 2025
Medpace Holdings Annual Report, Year Ended Dec 31, 2024
Medpace Holdings, Inc. (NASDAQ: MEDP) describes itself as one of the world's leading clinical contract research organizations by revenue, focused solely on outsourced Phase I-IV clinical development services for biotechnology, pharmaceutical and medical device companies. For the year ended December 31, 2024, net revenue was $2,109.1 million, up $223.2 million (11.8%) from $1,885.8 million in 2023. Income from operations rose to $446.9 million from $336.8 million, and net income increased to $404.4 million from $282.8 million, with diluted EPS of $12.63 compared with $8.88. Growth was described as broad based but primarily driven by Metabolic, Oncology, Cardiology and other uncategorized therapeutic areas. Net new business awards were $2,230.0 million in 2024 versus $2,356.7 million in 2023. Backlog rose $89.2 million, or 3.2%, to $2,902.2 million at December 31, 2024, of which approximately $1,620.0 million to $1,640.0 million is expected to convert to net revenue in 2025. Cash and cash equivalents increased to $669.4 million from $245.4 million, operating cash flow was $608.8 million, and the company had no indebtedness at year end. The company repurchased $174.2 million of stock in the fourth quarter alone for the year-ended 2024 program, and in February 2025 the Board added $600.0 million to its repurchase program. The filing highlights concentration and structural risks: the top ten customers generated approximately 28.9% of net revenue, most contracts are terminable on about 30 days' notice, and the CEO and founder, August J. Troendle, controls approximately 17.6% of outstanding shares. Deloitte & Touche LLP audited the financial statements and reported effective internal control over financial reporting as of December 31, 2024.
- 2023Feb 13, 2024
Medpace Holdings Annual Report, Year Ended Dec 31, 2023
Medpace Holdings, Inc. reported a strong 2023 in its 10-K filed February 13, 2024. Revenue, net rose $425.8 million, or 29.2%, to $1,885.8 million, up from $1,460.0 million in 2022. Income from operations reached $336.8 million, and net income was $282.8 million, compared with $245.4 million in 2022. Diluted EPS was $8.88, versus $7.28 a year earlier. Growth was broad based, driven mainly by Metabolic, Oncology, and AVAI therapeutic areas. Backlog grew $473.4 million, or 20.2%, to $2,813.0 million at December 31, 2023. Net new business awards were $2,356.7 million, up from $1,829.5 million. The company expects approximately $1,520.0 million to $1,540.0 million of backlog to convert to net revenue in 2024. The filing also notes that most customer contracts are terminable without cause on 30 days' notice, so backlog is not necessarily a meaningful predictor of future results. Cash and cash equivalents increased to $245.4 million from $28.3 million, and the company reported no outstanding indebtedness at year-end 2023. Operating cash flow was $433.4 million. The company repurchased $144.0 million of common stock during 2023 and had $308.8 million remaining under its current repurchase authorization. Risk factors highlight customer concentration (top ten customers at 29.5% of net revenue), fixed-fee contract exposure, and the influence of Chief Executive Officer and founder August J. Troendle, who controls approximately 20.8% of outstanding shares.
- 2022Feb 14, 2023
Medpace Holdings Annual Report, Year Ended Dec 31, 2022
Medpace Holdings, Inc. describes itself as one of the world's leading clinical contract research organizations (CROs) by revenue, solely focused on outsourced clinical development services for the biotechnology, pharmaceutical and medical device industries, with particular strength in Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI) and Central Nervous System (CNS). For 2022, net revenue rose 27.8% to $1,459,996 thousand ($1.46 billion) from $1,142,377 thousand, and net income increased to $245,368 thousand from $181,848 thousand. Diluted EPS was $7.28 versus $4.81. Backlog grew 17.2% to $2,339.6 million at December 31, 2022, with net new business awards of $1,829.5 million, and approximately $1,200.0 million to $1,220.0 million of backlog is expected to convert to net revenue in 2023. Balance sheet and cash flow shifted notably during the year. Cash and cash equivalents fell to $28.3 million from $461.3 million, largely because of $847.8 million in share repurchases, and short-term debt of $50.0 million was drawn under the revolving Credit Facility, which the filing says is expected to be amended or replaced before its March 31, 2023 expiration. Net cash provided by operating activities was $388.1 million. Total shareholders' equity fell to $386.4 million from $952.9 million, with an accumulated deficit of $359.8 million, reflecting the repurchases. The company had approximately 5,200 employees across 40 countries. The filing highlights several risks for investors: contracts are largely terminable on 30 days' notice, the backlog may not convert at historical rates, most Phase I–IV contracts are fixed-fee, and the Chief Executive Officer and founder, August J. Troendle, controls approximately 23.4% of outstanding shares. Deloitte & Touche LLP issued an unqualified opinion, and management concluded internal control over financial reporting was effective as of December 31, 2022.
- 2021Feb 15, 2022
Medpace Holdings Annual Report, Year Ended Dec 31, 2021
Medpace Holdings, Inc. (NASDAQ: MEDP) describes itself as one of the world's leading clinical contract research organizations by revenue, solely focused on outsourced clinical development services for the biotechnology, pharmaceutical and medical device industries, with particular strength in Oncology, Metabolic Disease, Cardiology, AVAI and CNS. For 2021, net revenue rose to $1,142.4 million from $925.9 million in 2020, an increase of 23.4%, driven primarily by Oncology, Metabolic, Central Nervous System and other therapeutic areas. Income from operations was $198.6 million versus $167.0 million, and net income was $181.8 million, or $4.81 per diluted share, compared with $145.4 million and $3.84 per diluted share in 2020. The effective tax rate fell to 9.9% from 13.7%, mainly due to higher excess tax benefits from share-based compensation and FDII benefits. Backlog ended 2021 at $1,997.1 million, up 29.5% from $1,541.7 million, and net new business awards were $1,610.4 million versus $1,175.0 million in 2020. The company expects approximately $1,030 million to $1,050 million of year-end backlog to convert to net revenue in 2022. Operating cash flow was $263.3 million, capital expenditures were $28.3 million, and cash and cash equivalents were $461.3 million at year-end, with no borrowings outstanding under its $50.0 million Credit Facility. The company repurchased $62.1 million of stock in 2021, and in February 2022 its board approved an additional $300 million repurchase authorization. The filing highlights risks including contract termination on short notice, backlog conversion, fixed-fee contract cost overruns, COVID-19 disruption, customer concentration among small and mid-sized biopharmaceutical companies (77% and 16% of 2021 net revenue, respectively), and founder and CEO August J. Troendle's control of approximately 17.2% of outstanding shares. Management reported effective internal control over financial reporting as of December 31, 2021.
- 2020Feb 16, 2021
Medpace Holdings Annual Report, Year Ended Dec 31, 2020
Medpace Holdings, Inc. (NASDAQ: MEDP) reported net revenue of $925.9 million for the year ended December 31, 2020, up $65.0 million from $861.0 million in 2019, with the filing attributing the increase primarily to strong activity in Oncology, AVAI and other uncategorized therapeutic areas. Income from operations rose to $167.0 million from $127.3 million, and net income increased to $145.4 million from $100.4 million, helped by a 13.7% effective tax rate versus 19.5% in 2019. Diluted EPS was $3.84 compared with $2.67 a year earlier. The filing states that COVID-19 had a significant adverse effect on fiscal 2020, reducing trial starts and slowing new business awards, and that management expects a continued adverse impact on results, though the duration and scope of the pandemic cannot be reasonably estimated. Net new business awards were $1,175.0 million in 2020 versus $1,094.4 million in 2019, and backlog grew to $1,541.7 million from $1,283.2 million, with approximately $785 million to $805 million expected to convert to net revenue in 2021. Balance sheet and cash flow were strengthened over the year: cash and cash equivalents reached $277.8 million, operating cash flow was $258.7 million, and the company had no borrowings under its $50.0 million unsecured Credit Facility. The company repurchased 1,183,095 shares for $98.3 million in 2020 and had $102.6 million remaining under its repurchase authorization. Investors should note the concentration of ownership: CEO and founder August J. Troendle controls approximately 20.2% of outstanding shares, and the company has never paid dividends.
- 2019Feb 25, 2020
Medpace Holdings Annual Report, Year Ended Dec 31, 2019
Medpace Holdings, Inc. is one of the world's leading clinical contract research organizations by revenue, focused solely on outsourced clinical development services for biotechnology, pharmaceutical and medical device companies. In 2019 total revenue rose to $860,969 thousand (about $861.0 million) from $704,589 thousand in 2018, driven primarily by strong activity in Oncology and other uncategorized therapeutic areas. Income from operations was $127,263 thousand, and net income was $100,443 thousand, or $2.67 per diluted share, compared with $73,185 thousand, or $1.97 per diluted share, in 2018. Net cash provided by operating activities was $201,867 thousand. Backlog grew to $1,283.2 million at December 31, 2019, up from $1,057.9 million, and net new business awards under ASC 606 were $1,094.4 million for 2019 versus $899.4 million for 2018. The company expects approximately $695 million to $715 million of backlog to convert to net revenue in 2020. The filing also notes concentration risk: the top 10 customers accounted for 28.8% of 2019 net revenue, the largest customer for 7.0%, and small biopharmaceutical companies for 71% of net revenue. Most customer contracts can be terminated without cause on 30 days' notice. The balance sheet at year-end 2019 showed cash and cash equivalents of $131,920 thousand and no outstanding debt under a new $50.0 million unsecured revolving Credit Facility. The company reports that it ceased to be an emerging growth company as of year-end 2019 and that August J. Troendle, its founder and CEO, controls approximately 23.2% of outstanding common stock. The company also remediated a material weakness related to ASC 606 implementation identified at December 31, 2018.
- 2018Feb 26, 2019
Medpace Holdings Annual Report, Year Ended Dec 31, 2018
Medpace Holdings, Inc. (MEDP) reported total revenue of $704.6 million for 2018 under ASC 606, compared with $436.2 million in 2017, and net income of $73.2 million, or $1.97 per diluted share, versus $39.1 million in 2017. The filing states that the increase was primarily driven by ASC 606 adoption, which added $155.2 million to 2018 revenue, with the remainder attributed mainly to strong Oncology and other therapeutic-area activity. On an ASC 605 basis, net new business awards were $581.0 million in 2018 and backlog was $626.1 million, up 19.4% from $524.4 million at year-end 2017. On an ASC 606 basis, backlog was $1,057.9 million, of which approximately $580 million to $600 million is expected to convert to revenue in 2019. The most important disclosure for investors is that management concluded internal control over financial reporting was not effective as of December 31, 2018, due to a material weakness related to the implementation of ASC 606. The company has developed a remediation plan, but the filing notes it may not be fully implemented in a timely or effective manner. The company's auditor, Deloitte & Touche LLP, issued an unqualified opinion on the financial statements and describes the adoption of ASC 606 under the modified retrospective approach. Balance sheet and capital structure items include cash and cash equivalents of $23.3 million, total debt of $80.4 million under the Senior Secured Term Loan Facility, and $149.8 million available under the undrawn Senior Secured Revolving Credit Facility at year-end. The filing also discloses a FINRA review of trading in the common stock surrounding the July 30, 2018 announcement of second-quarter 2018 results, and states that Dr. August J. Troendle, the CEO and founder, controls approximately 24.5% of outstanding shares.
- 2017Feb 27, 2018
Medpace Holdings Annual Report, Year Ended Dec 31, 2017
Medpace Holdings, Inc. is one of the world's leading clinical contract research organizations, by revenue, solely focused on outsourced clinical development services for biotechnology, pharmaceutical and medical device companies. For the year ended December 31, 2017, net service revenue was $386.5 million, up from $370.6 million in 2016, and net income was $39.1 million, compared with $13.4 million in 2016. Income from operations rose to $64.9 million from $52.5 million. Backlog grew by $40.5 million, or 8.4%, to $524.4 million at year-end, and net new business awards were $426.1 million for 2017. The company generated 64% of net service revenue from small biopharmaceutical companies, 25% from mid-sized companies and 11% from large pharmaceutical companies. Its top 10 customers accounted for 32.2% of net service revenue, and its largest customer for 5.3%. The balance sheet and capital structure are shaped by Cinven, a private equity owner, and founder Dr. August J. Troendle, who together control a substantial majority of common stock. Cinven owned approximately 46.2% and Dr. Troendle about 29.2% at December 31, 2017. Total indebtedness was $222.6 million, comprising $152.6 million of term loan and $70.0 million of revolver borrowings, and the company was in compliance with its financial covenants. During 2017 the company repurchased shares from Cinven in two transactions of 2,000,000 shares each, at $30.27 and $30.16 per share, and repurchased $155.6 million of common stock in total for the year. The filing also notes that Cinven-affiliated entities pledged their shares as collateral for a separate credit agreement, which could eventually affect controlled-company status. The filing highlights risks including customer concentration, the potential for cancellations and backlog not converting at historical rates, fixed-fee contract overruns, foreign currency exposure (7.6% of revenue in non-U.S. dollar currencies), and the effects of the Tax Cuts and Jobs Act. The 2017 effective tax rate was 31.3%, reduced by tax reform, which the company estimates would otherwise have been 36.2%.
- 2016Feb 28, 2017
Medpace Holdings Annual Report, Year Ended Dec 31, 2016
Medpace Holdings, Inc. (MEDP) reported Successor full-year 2016 net service revenue of $370.6 million, up $50.5 million or 15.8% from $320.1 million in 2015, and total revenue of $421.6 million. Net income was $13.4 million, compared with a net loss of $8.7 million in 2015. Income from operations rose to $52.5 million from $20.6 million, helped by lower amortization and the absence of a 2015 goodwill impairment, while direct costs grew 21.3% to $198.5 million on added headcount. The company describes itself as one of the world's leading clinical CROs, focused on full-service Phase I-IV development for small and mid-sized biopharmaceutical companies, which it says make up 64.8% and 23.0% of net service revenue respectively in 2016. Backlog rose 12.6% to $483.9 million at December 31, 2016, and net new business awards were $427.0 million, versus $359.5 million in 2015. The filing states that approximately $265 million to $275 million of backlog is expected to convert to net service revenue in 2017. Backlog is terminable without cause in most cases, and the filing cautions that it may not be a reliable predictor of future results. The company completed its IPO on August 11, 2016 at $23.00 per share, raising net proceeds of about $173.6 million, which were used to repay $175.0 million of 2014 term loan borrowings. Ownership and leverage are key investor considerations. Cinven owned approximately 56.5% of outstanding shares and founder Dr. August J. Troendle controls about 25.6% as of December 31, 2016, making the company a controlled company under NASDAQ rules. At year-end, total debt was $165.0 million under a new Senior Secured Term Loan Facility, with a $150.0 million undrawn revolver, and goodwill and intangibles represented 81.4% of total assets.